Andrew Warmington has been writing about pharmaceuticals and related industries since becoming editor of Speciality Chemicals Magazine in 2002. His particular area of expertise is in the C(D)MO drug substance and CRO markets, plus some on the regulatory side developed during an 18-month stint with Chemical Watch. During this time, he has attended every CPhI Worldwide plus other key industry events, such as Informex/CPhI North America, DCAT Week and PharmaChem Outsourcing, where he has been a regular moderator of expert panels. He has also been a freelance proof-reader within the industry, notably for a major drug packaging company. Andrew has a PhD in History, and speaks French and Spanish, plus just enough Italian to get by. In his spare time, he is a would-be true crime writer, a TV quiz veteran and a sad cricket fan who would happily hibernate when the season is over…
Latest from Andrew Warmington
As GLP-1 agonists surge to blockbuster status transforming diabetes and obesity treatment, Richard DiMarchi, the pioneering scientist behind their development, recounts the inside story of the drug class in a fireside chat.
Discover Henlius’ groundbreaking achievements, and their mission to deliver affordable, innovative drugs worldwide through strategic partnerships.
Discover Henlius’ groundbreaking achievements, and their mission to deliver affordable, innovative drugs worldwide through strategic partnerships.
In Sept 2024, a new CMDO, DMX Pharma, emerged on the global market. Explore the benefits of this merger, from production capacity to cross-selling capability, regulatory expertise and their ambitious future plans.
Rising star Agnė Vaitkevičienė is juggling roles as the CEO of an emerging Lithuanian biotech, with work for a partner company, the national biotech trade association and much more.
Biotech investment is in abeyance after an unprecedented twelve-year run, according to Gregg Beloff, managing director of Danforth Advisors. The capital markets will be back and industry must continue to operate while the bear market persists.